Add To Watchlist
Share URL
About The Company
Description
Genovis AB (publ.) designs, develops, and sells tools for development of drugs for customers in the pharmaceutical and medical device industries.
Read More
Overview
Value
3
Growth
68
Health
81
Management
56
Analyst Opinion
80
Total
58
All Scores Out Of 100
Best Features
- Very strong cashflow and earnings growth
- Earnings growth has improved recently
- Has a low level of debt
- Low risk of bankruptcy
- Has strong financial health
- Liked by analysts
- Low preportion of income is paid as dividend
Risk Factors
- Overvalued on cashflow basis
- There is a history of diluting shareholders
- No margin of safety at their current market price
- Price-to-earnings ratio of 92.9 is higher than the market average (19.6x) 0
Market Peers
GENO.ST
Key Figures
PE Ratio (TTM)
92.87
Margin Of Safety (DCF)
-88.85%
Revenue Growth (5 Year Average)
7.96%
Ratings Consensus
Buy
Share Buybacks
-0.46%
Dividend Yeild (TTM)
N/A
Valuation
Value Score
3
Desired Margin Of Safety
0%
▼
Tip: Set your desired Margin Of Safety
Free Cash Flow Type
Annual Cashflow Growth
0%
Discount Rate
0%
Buy Target: < 3.2 SEK ✘
Current Price: 58.1 SEK
How Does This Work?
Show Advanced Options
This calculator helps investors estimate the Intrinsic Value of a company based on the current value of future cash flows. To use the tool, simply input a desired Margin Of Safety, which is an additional discount applied to the present value of the expected future cash flows. The tool calculates the present value using a discount rate that reflects the risk and time value of money, and provides an estimated target price for the company based on the selected margin of safety. The calculator defaults to using 5 Year Free Cash Flow Growth % and a discount rate based on the US 10-year treasury bond coupon rate. Use our performance analyser to get a feel the impact this has on longterm investment returns and discover a margin of safety you are comfortable with. This can be a useful tool for investors looking to make informed decisions about whether to buy or sell shares of a particular company.
Price/Earnings
92.87x
Free Cashflow Yeild
1.01%
PE/Earnings Growth
0.12
Price/Book
29.87x
Growth
Growth Score
68
- ✔ Revenue growth has improved this yeara
- ✔ 5 Year Average Earnings growth of 18.09% is higher than the market average (14.48%)
- ✔ Earnings growth has improved this year
- ✔ 5 Year Average Cashflow growth of 28.48% is higher than the market average (12.35%)
- ✘ 5 Year Average Revenue growth of 7.96% is lower than the market average (10.97%)
- ✘ Free Cashflow growth has slowed this year
Revenue Growth
7.96%
Earnings Growth
18.09%
Cashflow Growth
28.48%
Health
Health Score
81
Altman Z Score
20.00
Piostroski Score
7.00
Debt/Equity
N/Ax
Current Assets/Liabilities
7.96x
Free Cashflow/Total Debt
N/Ax
Debt/Capital
N/Ax
Management
Management Score
56
Average Buybacks/Dilution
-0.46%
Recent Buybacks/Dilution
4.29%
5 Year Price Volitility
63.48%
Return On Assets
3.78%
Return On Capital Employed
5.26%
Return On Equity
4.48%
Return On Free Cashflow
3235.14%
Return On Investments
57.10%
Analysts
Analyst Opinion
80
- ✔ Ratings consensus is Buy
SEC Filings
Find yearly (10-K), quaterly (10-Q) and disclosure (8-K) report here, on the Securities and Exchange Commission's EDGAR database. If reading through reports isn't your cup of tea, don't worry. We've made it easy for you by summarizing all the important bits.
Other Information
Company Name
Currency
SEK
Beta
Vol Avg
Ceo
Cik
Cusip
Exchange
Stockholm Stock Exchange
Full Time Employees
Industry
Biotechnology
Sector
Healthcare
Ipo Date
Address
ScheelevAegen 2
City
Lund
State
Country
Zip
220 07
Phone
46 46 10 12 30
All financial data provided by FMP